Evidence map›Paper›PMID 34605706›Full record

Observational studyTechnology in cancer research & treatment

Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.

Sung E Oh, Ji Y An, Min-Gew Choi, Jun H Lee, Tae S Sohn, Jae M Bae

Open access · goldAbstract readComparative StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sung E Oh36626Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0002-5907-3840
Ji Y An36626Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Min-Gew Choi36626Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jun H Lee36626Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Tae S Sohn36626Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jae M Bae36626Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Samsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemotherapy, AdjuvantDisease-Free SurvivalDrug CombinationsFemaleGastrectomyHumansLymph Node ExcisionMaleMiddle AgedNeoplasm StagingOxaliplatinOxonic AcidRetrospective StudiesAntimetabolites, AntineoplasticCapecitabineDrug CombinationsOxaliplatinOxonic AcidS 1 (combination)Tegafuradjuvant chemotherapycapecitabine and oxaliplatin (XELOX)gastric cancerprognosisS-1 monotherapysurvival

Identifiers

PMID34605706
PMCPMC8493307
OpenAlexW3201760133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.